Dengfu Yao

List of Publications by Year
in descending order

33 papers	659 citations	623734 14 h-index	677142 22 g-index
36 all docs	36 docs citations	36 times ranked	849 citing authors

#	Article	IF	Citations
1	Abnormal expression of hepatoma specific ?-glutamyl transferase and alteration of ?-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. , 2000, 88, 761-769.		120
2	Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumor Biology, 2014, 35, 9-20.	1.8	61
3	Characteristics of Hepatic IGF-II Expression and Monitored Levels of Circulating IGF-II mRNA in Metastasis of Hepatocellular Carcinoma. American Journal of Clinical Pathology, 2010, 134, 799-806.	0.7	43
4	Expression characteristics of HIF-1Î± and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepatitis Monthly, 2011, 11, 821-828.	0.2	39
5	Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3Î²/Î²-catenin axis. Journal of Translational Medicine, 2020, 18, 81.	4.4	33
6	Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. Tumor Biology, 2015, 36, 9373-9383.	1.8	32
7	Expression Characteristics of Hypoxia-Inducible Factor-1Î± and Its Clinical Values in Diagnosis and Prognosis of Hepatocellular Carcinoma. Hepatitis Monthly, 2011, 11, 821-828.	0.2	27
8	Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumor Biology, 2012, 33, 1767-1776.	1.8	24
9	The application of bio-nanotechnology in tumor diagnosis and treatment: a view. Nanotechnology Reviews, 2018, 7, 257-266.	5.8	22
10	Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy. Tumor Biology, 2014, 35, 5857-5868.	1.8	21
11	Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma. Oncotarget, 0, 7, 42150-42158.	1.8	21
12	Oncogenic Wnt3a: A Candidate Specific Marker and Novel Molecular Target for Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 5862-5873.	2.5	20
13	Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. Tumor Biology, 2016, 37, 999-1008.	1.8	17
14	Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepatitis Monthly, 2015, 15, e32918.	0.2	17
15	Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. Tumor Biology, 2015, 36, 3995-4003.	1.8	16
16	Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget, 2017, 8, 52321-52332.	1.8	16
17	Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. BioScience Trends, 2016, 10, 337-343.	3.4	14
18	Role of secretory clusterin in hepatocarcinogenesis. Translational Gastroenterology and Hepatology, 2018, 3, 48-48.	3.0	14

#	Article	IF	Citations
19	Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. Tumor Biology, 2016, 37, 5561-5568.	1.8	13
20	High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma. Cancer Management and Research, 2018, Volume 10, 5979-5989.	1.9	13
21	Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA. Tumor Biology, 2013, 34, 661-668.	1.8	12
22	Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumor Biology, 2010, 31, 605-611.	1.8	11
23	Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 453-460.	1.7	10
24	Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. Tumor Biology, 2013, 34, 3397-3405.	1.8	8
25	Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma. Mini-Reviews in Medicinal Chemistry, 2015, 14, 1183-1193.	2.4	8
26	IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. Tumor Biology, 2016, 37, 14677-14686.	1.8	7
27	Abnormal expression of hepatoma specific Î³â€glutamyl transferase and alteration of Î³â€glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer, 2000, 88, 761-769.	4.1	5
28	Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Current Medicinal Chemistry, 2020, 27, 3290-3301.	2.4	5
29	Abnormal expression of hypoxia inducible factor-1Î± and clinical values of molecular-targeted interference in hepatocellular carcinoma. Chinese-German Journal of Clinical Oncology, 2012, 11, 125-129.	0.1	3
30	Expression of Src Suppressed C Kinase Substrate in Rat Neural Tissues During Inflammation. Neurochemical Research, 2014, 39, 748-757.	3.3	2
31	Quantitative analysis of hepatoma-specific Î±-fetoprotein (HS-AFP) by a new mini-column affinity chromatography and its clinical value in diagnosis of hepatocellular carcinoma. Chinese-German Journal of Clinical Oncology, 2008, 7, 131-134.	0.1	1
32	Clinic expert information extraction based on domain model and block importance model. Computers in Biology and Medicine, 2015, 66, 337-342.	7.0	1
33	Oncogenic Secretory Clusterin: A Promising Therapeutic Target for Hepatocellular Carcinoma. , 0, , .		0